What is a Bladder Cancer Molecular Subtype? - Counterpoint.

Bladder Cancer

Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Published: December 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In an accompanying paper, Mattias Höglund discusses on what is a bladder cancer molecular subtype. He emphasizes the need to consider the aim of tumor classification, which is obviously critical to the approach. He also focuses on considering primarily the identity features of the neoplastic cells. Here, we provide a counterpoint. While largely agreeing with his views, we underline that other parameters that may vary in a spatial or temporal scale, and the tumor microenvironment, can also provide relevant information to render tumor classifications clinically useful. Furthermore, tumor heterogeneity and evolution during the disease course - natural or under therapeutic pressure - should be considered.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11165934PMC
http://dx.doi.org/10.3233/BLC-230059DOI Listing

Publication Analysis

Top Keywords

bladder cancer
8
cancer molecular
8
molecular subtype?
4
subtype? counterpoint
4
counterpoint accompanying
4
accompanying paper
4
paper mattias
4
mattias höglund
4
höglund discusses
4
discusses bladder
4

Similar Publications

Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.

View Article and Find Full Text PDF

Long-term complications in patients with bladder-prostate rhabdomyosarcoma treated with brachytherapy: a systematic review.

Pediatr Surg Int

September 2025

Pediatric Surgery Unit, Department of Women's and Children's Health, University of Padua, Via Nicolò Giustiniani, 35100, Padua, Italy.

Introduction: Brachytherapy has been used for the multimodal treatment of pediatric bladder-prostate rhabdomyosarcoma in the last two decades. The aim of this systematic review is to gather the current evidence about this innovative technique with a special focus on long-term outcomes.

Methods: According to PRISMA criteria, PubMed, Scopus, and Web of Science were searched for papers published between 2000 and 2022.

View Article and Find Full Text PDF

Background: High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative.

View Article and Find Full Text PDF